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In this paper, analysis strategies developed for a sequencing problem concerning the
identification of an S100 protein isolated from human granulocytes are discussed. The analysis
of a trypsinized lyophilized sample suggested the presence of a number of peptides which are
non-tryptic in origin. During purification of proteins from cell lysates nonspecific cleavage can
be observed which may reflect biological processes and can become an unavoidable analytical
problem. Current mass spectrometric software is evaluated for the analysis of nonspecific
digests in this context. Matrix-assisted laser desorption ionization mass spectrometry (MALDI-
MS), high-performance liquid chromatography (HPLC)-MS/MS, and selected ion monitoring
(SIM)-MS/MS have been used for peptide analysis and in addition HPLC-MS was carried out
for protein analysis leading to the detection of an N-terminal modification of the protein. The
success of the study is mainly due to the careful investigation of nonspecific cleavage products.
Data obtained from the routine mass spectrometric analysis of an in-gel-digest allowed the
identification of this protein as S100 calcium-binding protein A6–calcyclin whose expression
in granulocytes has not been described so far. (J Am Soc Mass Spectrom 2001, 12, 1180–1185)
© 2001 American Society for Mass Spectrometry
In human granulocytes three members of the S100family of calcium-binding proteins have been iden-tified, namely MRP8 (myeloid related protein 8,
S100A8), MRP14 (S100A9), and S100A12, representing
up to 40% of the cytosolic protein content in these cells
[1]. Due to their capacity for calcium binding they are
considered to be involved in signal transduction events.
During purification of MRP8 and MRP14 from gran-
ulocytes, another protein was co-isolated which had not
been identified so far. Tryptic digestion of the lyophi-
lized protein followed by peptide mapping and frag-
mentation analysis were carried out, but did not, sur-
prisingly, produce conclusive results about the identity
of the protein. This seemed to be due to the fact that a
number of peptides were present which shared parts of
their sequence, but were not tryptic in origin. We found
ourselves confronted with a mixture of a large number
of undefined peptides which forced us to devise the
more extensive analysis strategies presented here. For
data analysis, publicly and locally available mass spec-
trometric software has been evaluated for the special
analysis tasks required in that particular case.
Nonspecific cleavage products have been observed
as byproducts in enzymatic digestions and they have
been detected using MS [2–4]. In general, unexpected
and therefore unwanted products are generated which
decrease the amount of specifically cleaved peptides
available for detection. Nonspecific cleavage can be an
indicator for the presence of other active proteases in
the sample and lead to enforcement of precautions such
as the use of inhibitors. However, detection of such
peptides can also reflect biological processes such as
protein degradation in cells because of regulatory cycles
as revealed with affinity pull-downs. Nonspecific cleav-
age using a cocktail of enzymes is usually only per-
formed intentionally in cases where the complete deg-
radation to the amino acid components of the protein is
the goal. We became aware that the detection of unspe-
cific cleavage products can be an unavoidable analytical
problem as well as a useful analytical tool. Careful
study of its products enhanced the outcome of our
analysis considerably especially with regard to modifi-
cations of the protein.
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Experimental
Granulocytes were prepared from human buffy coats
by Ficoll-Paque (Pharmacia, Freiburg, Germany) cen-
trifugation [5, 6]. The protein purification procedure
was developed originally to purify MRP8/MRP14 from
human granulocytes and is described in detail else-
where [7]. Briefly, granulocytes were lysed in homoge-
nization buffer (20 mM Tris/HCl, 1 mM DTT, 1 mM
EDTA, 1 mM EGTA, pH 8.5) supplemented with a
protease inhibitor cocktail including 1 mM PMSF, 20
M Leupeptin, 25 g/ml Aprotinin, 0.2 mM PEFA-
Block and with phosphatase inhibitors including 100
mM NaF and 1 mM Na3VO4 using a Branson sonifier
model 250 (Branson Ultrasonics, Danbury, CT). After
centrifugation the majority of proteins was precipitated
by addition of 70% ammonium sulfate. The main frac-
tion of S100 proteins remained in the supernatant. After
dialysis of the supernatant, anion exchange chromatog-
raphy was carried out using fast protein liquid chroma-
tography (FPLC; Kontron Instruments/Wicon, Hep-
penheim, Germany) on a equilibrated Pharmacia Q
Sepharose column model 26/10. Various fractions re-
tained from anion-exchange chromatography (linear
gradient from 0 to 1M NaCl) were collected. Two main
fractions containing MRP8/MRP14 were collected elut-
ing at a NaCl concentration of 175 mM and 240 mM,
respectively. Another main fraction containing phos-
phorylated MRP8/MRP14P was eluted at an even
higher NaCl concentration. At the beginning of the first
8/14 elution, the fractions were contaminated by an-
other protein with a molecular mass of 6.5 kDa on a
Coomassie-stained sodium dodecylsulfate (SDS)-Gel.
We have chosen these fractions for further purification
and identification of the unknown band. Using hydro-
phobic interaction chromatography (phenyl-sepharose)
it was possible to separate the unknown protein from
MRP8/MRP14. The identity of these S100 proteins was
ascertained by amino acid sequencing and MS [8].
Before each measurement, all samples were routinely
dialyzed against 20 mM TRIS, pH 7.5 in the presence of
1 mM DTT.
For this study, the protein solution was investigated
directly as well as the gel spot produced by 1D-SDS-
polyacrylamide gel electrophoresis (PAGE) (15%).
Tryptic digestion was carried out both in-gel and in-
solution. After SDS-PAGE the gel spot was prepared for
MS in a procedure modified from references [9, 10]. The
gel slice was excised and destained in 25 mM
NH4HCO3 containing 50% methanol. It was washed in
acetic acid/methanol/water 10/45/45 vol/vol/vol for
30 min and in water for 30 min after which it was
shrunk in acetonitrile and dried. The gel slice was
reswollen in 20 l of 50 mM NH4HCO3 containing 400
ng trypsin (Boehringer-Mannheim, Mannheim, Germa-
Figure 1. MALDI peptide maps of digests of gel (top trace) and solution (bottom trace). Peaks are
labeled with tryptic peptides found. In solution, the peak at m/z 2314.47 indicates the modification of
the N-terminal peptide by loss of M and acetylation of the following A.
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ny). Extra trypsin solution was removed and enough
buffer was added to cover the gel slice. Digestion was
carried out at 37 °C overnight. Digestion was stopped
by adding 5–10 l of 100% acetic acid and the superna-
tant was removed to a clean Eppendorf tube. The gel
slice was extracted twice with 70 l acetonitrile and
supernatants were pooled and lyophilized. The dried
extract was redissolved in 7 l 0.1% aqueous trifluoro-
acetic acid (TFA) (Merck, Darmstadt, Germany) and
purified using ZipTips (Millipore, Bedford, MA). Pep-
tides were eluted with 7 l 70% acetonitrile. 10 mg
-cyano-4-hydroxycinnamic acid (Sigma, Deisenhofen
Germany) were washed with acetone and dissolved in 1
ml of 50/50 vol/vol acetonitrile/ethanol containing 1%
of 0.1% aqueous TFA. 0.7 l of this matrix preparation
was spotted onto the target followed by the same
amount of sample and both solutions were mixed
directly on the target for MALDI peptide mapping on
TofSpec 2E (Micromass Ltd., Manchester, UK). Digests
were run in positive ion reflectron mode using a matrix
suppression of 500. Masses were externally calibrated
and internally corrected using either the lock mass
option of the instrument or trypsin autolysis peaks
providing m/z values better than 50 ppm up to m/z 2500.
Peptide HPLC-MS/MS and protein HPLC-MS were
carried out using HP1100 (Agilent, Palo Alto, CA) and
Esquire3000 (Bruker, Bremen, Germany) with a 180 m
PepMap column (LC-Packings, Amsterdam, The Neth-
erlands). HPLC solvents were water/acetonitrile con-
taining 0.1% formic acid. A 60 min gradient was used.
For HPLC-SIM experiments the ion trap target mass
was set to the mass of interest and automatic fragmen-
tation was programmed. The mass accuracy of the ion
trap experiments was better than 0.4 Da.
Fragmentation was carried out on the purified di-
gests using Q-TOF (Micromass, Beverly, MA). Nano-
spray was generated with self-pulled omega glass cap-
illaries and an internally applied high voltage of 1 kV
using a stainless steel wire inside the capillary [11, 12].
Argon was used as collision gas.
Data analysis was performed using the MS database
search programs Mascot (Matrix Science Ltd., London,
UK), Protein Prospector (University of California, San
Francisco, CA), PeptideSearch (European Molecular Bi-
ology Laboratory, Heidelberg, Germany), ProteinProbe
(Micromass), BioTools (Bruker), GPMAW (Lighthouse
Data, Odense, Denmark), and Prowl (Rockefeller Uni-
versity, New York).
Results
The in-solution tryptic digest following routine proto-
cols did not provide positive assignment of the protein
while MS analysis of the in-gel-digest led to the identi-
Figure 2. MS/MS spectra of nanospray measurements using Q-TOF (doubly charged parent ions m/z
756.9, 807.4, 881.0, 937.5). Shown is a series of peptides derived from the C-terminal peptide with two
missed cleavages and C-terminal degradation. Both the y- and the b-ion series can be observed
although the latter appears at higher intensity.
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fication of this protein as S100 calcium-binding protein
A6–calcyclin (NCBI 7657532). The MALDI peptide
maps are shown in Figure 1. The top trace represents
the peptide map of the in-gel digest and clear assign-
ments of tryptic peptides can be made while the map of
the in-solution digest does not provide such a charac-
teristic picture. Deducing from the in-gel digest result it
became evident that the in-solution digest contained a
number of unexpected peptides belonging to calcyclin.
In fact, peptides possibly resulting from carboxypepti-
dase ladder digest, proteinase K, chymotryptic or other
unspecific protease digest can be observed, although a
protease inhibitor cocktail had been used to avoid
proteolysis during protein isolation.
Using MS/MS after in-gel digest the midchain tryp-
tic peptides from amino acids 33 to 62 were found and
a MALDI-signal could be observed for the C-terminal
peptide. Nanospray-MS/MS after in-solution digest
provided several fragmentation spectra of nonspecifi-
cally cleaved peptides, examples of which are shown in
Figure 2 for peptides towards the C-terminus. The
peptides share the sequence but they are truncated to a
different degree at their C-terminal end. In nanospray
the possibility of in-source fragmentation has to be
considered. To exclude this effect we worked with
reduced cone voltage. In addition, the in-solution digest
was separated using a C18-reversed phase column per-
forming on-line HPLC-MS/MS on the ion trap Es-
quire3000. In this way artifacts generated by in-source
fragmentation can be ruled out by their retention times.
Using data produced by automatic MS-MS/MS switch-
ing, deconvoluted spectra were calculated with Data-
Analysis software (Bruker) and a database search was
performed using Mascot. The enzyme was set to “none”
in this case. Setting it to “tryptic” did not provide
significant hits. The results of this search are exhibited
in Figure 3 showing a high score of 293 which is due to
several MS/MS spectra which were assigned with great
probability to nonspecifically cleaved peptides located
at the C-terminus of the protein. Since automatic
MS/MS analysis is constrained by an appropriate set of
search criteria it cannot be expected to be complete. In
this case about 20% of the peptides were found auto-
matically which could be assigned manually. Besides
Mascot, which is a publicly available MS software, also
Protein Prospector allows automatic detection of pep-
tides resulting from nonspecific cleavage using MS/MS
data. This is because in-source fragmentation can be
expected to some extent in electrospray and provisions
have to be made to detect those nonspecific fragments.
However, none of the major programs available on the
internet provides the “no enzyme” option for peptide
mapping. Of some help is the Prowl software program,
offering a way to calculate the unspecific digest of
proteins obtainable from databases which can then be
checked manually against the spectrum. Most locally
available software (ProteinProbe, GPMAW, BioTools)
accompanying the instruments can be modified to serve
this purpose and requires user input to different de-
grees.
Analyzing the HPLC-MS/MS data by further man-
ual screening of all spectra for peptides expected by
both nonspecific and tryptic cleavage from calcyclin,
several more peptides were found as given in Table 1.
Adding the Q-TOF data shown in Table 2, we had
proven the presence of peptides covering the whole
sequence of calcyclin except the N-terminus. We fol-
lowed up on that screening for tryptic peptides from
that region using SIM. For these experiments the ion
trap target mass was set to the mass under investiga-
tion, thereby enhancing the sensitivity. The experiments
provided sequence data for two more missing peptides
located in the N-terminal region. Although it was
possible to assign part of the N-terminal peptide amino
acid residues 1–18, the first ten amino acid residues of
the calcyclin sequence could not be verified. Below we
show in bold the parts of the sequence identified with
fragmentation data.
MACPLDQAIG LLVAIFHKYS GREGDKHTLS
KKELKELIQK ELTIGSKLQD AEIARLMEDL
DRNKDQEVNF QEYVTFLGAL ALIYNEALKG
In order to clarify some suspicion that the protein
might be modified N-terminally as seen for MRP14
before [8], we performed HPLC-MS of the undigested
protein solution. As expected, a number of peptides
Database: NCBInr 20001111 (582290 sequences; 183345511
residues)
Taxonomy: Homo sapiens (human) (71346 sequences)
Significant hits: gi/7657532 S100 calcium-binding protein A6;
prolactin receptor-associated protein
Enzyme: None
Mass values: Monoisotopic
Mass tolerance:  0.4 Da
Figure 3. Database search using Mascot with peak lists obtained
with automatic HPLC-MS/MS. Shown are the parameters set such
as the cleavage is given as nonspecific and the output created by
the program. MS/MS spectra have been found for non-tryptic
C-terminal peptides with a high score.
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were present in the solution which were not studied
further. The bulk of the solution consisted of a protein
with the mass of 10,091 Da with an error 1 Da as well
as its covalent dimer at 20,180 Da. Calcyclin is a protein
with a theoretical mass of 10,179.8 Da. The mass differ-
ence of the protein found at 10,091 Da to the theoretical
mass of calcyclin could be due to a removal of the
N-terminal methionine and the acetylation of the
following alanine. This has been observed for MRP14
[8] and it is consistent with MALDI results as indi-
cated in Figure 1. The formation of the dimer can be
explained by the presence of one cysteine forming
one disulfide bridge, if the solution conditions are not
reducing enough. Preceding in retention time but
attached to the main peak another protein is detected
at 10,163 Da. Since all experimental results point to
calcyclin, we assume this protein represents another
N-terminal modification of calcyclin. Partial MS/MS
data supporting the above theory could be produced,
but more experiments will have to be carried out in
order to fully describe the modifications in both
proteins.
The expression of S100A6 has not been described in
human granulocytes to date. The S100A6 gene was
originally identified as a cell cycle dependent gene that
displayed increased expression in G1. It has been
shown that calcyclin expression is upregulated in the
cells of patients with acute myeloid leukemia and in
certain breast cancer and melanoma cell lines [13–15].
Expression of calcyclin was also found in Ehrlich ascites
tumour (EAT) cells [16] as well as in human epithelial
cells and fibroblasts [17].
Conclusion
Another S100 calcium-binding protein, A6–calcyclin,
was identified from human granulocytes employing
standard protein sequencing procedures. Extensive
analysis of nonspecific peptides present in the digest of
the protein solution using HPLC- MS/MS, and HPLC-
SIM-MS/MS as well as HPLC-MS of the undigested
protein lead to proof of the expected sequence and
suggested N-terminal modifications of calcyclin. Cur-
rent MS software support of the analysis of nonspecific
digests is limited.
In granulocytes, expression of S100A6 has not been
described so far and further experiments on the calcy-
clin RNA level will be carried out.
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